19. Tomasetti C*, Li L, Vogelstein B.  Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention.  Science 2017, 355(6331):1330-1334.

18. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Horlings HM, Noe M, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu R-C, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen J, Wong F, Hasanovic A, Orr N, Wang M, Popoli M, McMahon W, Wood L, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang T-L, Vogelstein B, Yong PJ, Huntsman DG, Shih I-M.   Cancer associated mutations in non-cancer associated endometriosis.  N Engl J Med 2017, 376(19):1835-1848.

17. Tomasetti C*, Vogelstein B.  On the slope of the regression between stem cell divisions and cancer risk, and the lack of correlation between stem cell divisions and environmental factors-associated cancer risk.  PLoS ONE 2017, 12(5):e0175535.

16. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, Tacey M, Wong H, Christie M, Kosmider S, Skinner I, Wong R, Steel M, Tran B, Desai J, Jones I, Haydon A, Hayes T, Price TJ, Strausberg RL, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.  Sci Transl Med 2016, 8(346):346ra92.

15. Hoang ML, Kinde I, Tomasetti C, McMahon KW, Rosenquist TA, Grollman AP, Kinzler KW, Vogelstein B, Papadopoulos N.  Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing.  Proc Natl Acad Sci USA 2016, 113(35):9846-9851.

14. Tomasetti C*, Vogelstein B.  Cancer risk: role of environment – Response.  Science 2015, 347(6223):729-731.

13. Tomasetti C*, Vogelstein B.  Variation in cancer risk among tissues can be explained by the number of stem cell divisions.  Science 2015, 347(6217):78-81.

12. Tomasetti C*, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B.  Only three driver gene mutations are required for the development of lung and colorectal cancer.  Proc Natl Acad Sci USA 2015, 112(1):118-123.

11. Tomasetti C*, Bozic I.  The (not-so) immortal strand hypothesis.  Stem Cell Research 2015, 14(2):238-241.

10. Geman D, Ochs M, Price ND, Tomasetti C, Younes L.  An argument for mechanism-based statistical inference in cancer.  Human Genetics 2014, DOI:10.1007/s00439-014-1501-x.

9. Tomasetti C*, Demetri GD, Parmigiani G.  Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.  F1000Research 2013, 2:152.

8. Tomasetti C*, Vogelstein B, Parmigiani G.  Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation.  Proc Natl Acad Sci USA 2013, 110(6):1999-2004.

7. Tomasetti C*.  Stochastic modeling of multiple random genetic mutations under the cancer stem cell hypothesis.  Mathematical Population Studies 2012, 19(4):200-213.

6. Tomasetti C*.  On the probability of random genetic mutations for various types of tumor growth.  Bulletin of Mathematical Biology 2012, 74(6):1379-1395.

5. Tomasetti C*.  A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells.  Blood Cancer Journal 2011, 1:e19.

4. Tomasetti C*, Levy D.  Role of symmetric and asymmetric division of stem cells in developing drug resistance.  Proc Natl Acad Sci USA 2010, 107(39):16766-16771.

3. Galante A, Levy D, Tomasetti C*.  A mathematical model for microenvironmental control of tumor growth.  IFMBE Proceedings 2010, eds Herold KE, Vossoughi J, Bentley WE, Springer, Berlin, 32.

2. Tomasetti C*, Levy D.  Drug resistance always depends on the turnover rate.  IFMBE Proceedings 2010, eds Herold KE, Vossoughi J, Bentley WE, Springer, Berlin, 32.

1. Tomasetti C*, Levy D.  An elementary approach to modeling drug resistance in cancer.  Math Biosci Eng 2010, 7(4):905-918.